RSCM
KYMR icon

Rock Springs Capital Management’s Kymera Therapeutics KYMR Stock Holding History

Rock Springs Capital Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52M Sell
453,156
-43,715
-9% -$3.76M 2.54% 7
2026
Q1 		$41.4M Hold
496,871
– – 2.44% 11
2025
Q4 		$38.7M Buy
496,871
+46,497
+10% +$3.14M 1.98% 15
2025
Q3 		$25.5M Hold
450,374
– – 1.49% 24
2025
Q2 		$19.7M Sell
450,374
-344,063
-43% -$11.8M 1.22% 30
2025
Q1 		$21.7M Sell
794,437
-239,700
-23% -$8.74M 1.24% 29
2024
Q4 		$41.6M Sell
1,034,137
-15,249
-1% -$689K 1.58% 20
2024
Q3 		$49.7M Sell
1,049,386
-114,587
-10% -$5.06M 1.62% 22
2024
Q2 		$34.7M Sell
1,163,973
-358,265
-24% -$12.4M 1.05% 38
2024
Q1 		$61.2M Hold
1,522,238
– – 1.55% 21
2023
Q4 		$38.8M Buy
1,522,238
+17,887
+1% +$320K 0.95% 36
2023
Q3 		$20.9M Buy
1,504,351
+16,800
+1% +$338K 0.56% 56
2023
Q2 		$34.2M Buy
1,487,551
+259,172
+21% +$7.43M 0.81% 40
2023
Q1 		$36.4M Buy
1,228,379
+600
+0% +$19.4K 0.87% 44
2022
Q4 		$30.6M Buy
1,227,779
+181,036
+17% +$4.83M 0.74% 46
2022
Q3 		$22.8M Buy
1,046,743
+270,864
+35% +$7.14M 0.59% 50
2022
Q2 		$15.3M Buy
775,879
+20,004
+3% +$467K 0.44% 61
2022
Q1 		$32M Buy
755,875
+13,810
+2% +$583K 0.81% 42
2021
Q4 		$47.1M Buy
742,065
+9,138
+1% +$532K 1.09% 31
2021
Q3 		$43.1M Buy
732,927
+106,400
+17% +$6.17M 0.91% 38
2021
Q2 		$30.4M Buy
626,527
+4,750
+0.8% +$206K 0.6% 54
2021
Q1 		$24.2M Sell
621,777
-92,088
-13% -$5.54M 0.53% 66
2020
Q4 		$44.3M Buy
713,865
+3,900
+0.5% +$190K 0.94% 34
2020
Q3 		$22.9M Buy
+709,965
New +$21.7M 0.58% 58

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Rock Springs Capital Management's KYMR Position: Q2 2026 in Review

Rock Springs Capital Management reduced its Kymera Therapeutics (KYMR) stake by 8.8% in Q2 2026, selling an estimated $3.76M and leaving 453,156 shares worth $52M. The position accounts for 2.54% of the portfolio, ranked #7.

Rock Springs Capital Management first reported a position in KYMR in Q3 2020 and has held it in 24 quarters since. The position peaked at $61.2M in Q1 2024. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Rock Springs Capital Management held 453,156 shares of Kymera Therapeutics worth $52M as of Q2 2026.
  • Rock Springs Capital Management sold 43,715 Kymera Therapeutics shares in Q2 2026, an estimated $3.76M.
  • Kymera Therapeutics made up 2.54% of Rock Springs Capital Management's portfolio in Q2 2026, its #7 holding.
  • Rock Springs Capital Management first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • Rock Springs Capital Management's Kymera Therapeutics position peaked at $61.2M in Q1 2024.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.